Nuvectis Pharma (NVCT) Accumulated Expenses (2021 - 2026)
Nuvectis Pharma (NVCT) reported Accumulated Expenses of $36000.0 for Q1 2026, down 99.29% on a YoY basis from $5.0 million in Q1 2025, and down 68.7% sequentially from $115000.0 in Q4 2025.
Nuvectis Pharma (NVCT) Accumulated Expenses (2021 - 2026) Analysis & Trends
Nuvectis Pharma (NVCT) has 6 years of Accumulated Expenses data on file, last reported at $36000.0 in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses fell 99.29% year-over-year to $36000.0; the trailing twelve-month figure through Mar 2026 stood at $36000.0 (down 99.29% YoY), and the FY2025 full-year result was $115000.0, down 97.93% from the prior year.
- Accumulated Expenses declined to $36000.0 in Q1 2026, from $115000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $5.6 million in Q4 2024 to a low of $2000.0 in Q2 2025.
- A 5-year average of $1.9 million and a median of $863000.0 in 2022 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses soared 2287.97% in 2024 and sank 99.94% in 2025, its largest moves.
- Tracing NVCT's Accumulated Expenses over 5 years: stood at $445000.0 in 2022, then jumped by 753.48% to $3.8 million in 2023, then surged by 46.29% to $5.6 million in 2024, then sank by 97.93% to $115000.0 in 2025, then slumped by 68.7% to $36000.0 in 2026.
- Business Quant data shows NVCT's Accumulated Expenses at $36000.0 in Q1 2026, $115000.0 in Q4 2025, and $65000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Nuvectis Pharma | 471.80 Mn | 471.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 5.04 Mn |
| Dec 31, 2024 | 5.56 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 3.80 Mn |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 445,000.00 |
| Sep 30, 2022 | 863,000.00 |
| Jun 30, 2022 | 790,000.00 |
| Mar 31, 2022 | 697,000.00 |
| Dec 31, 2021 | 142,000.00 |